Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors

Lignende værker

• Nutrition Support for Head and Neck Squamous Cell Carcinoma Patients Treated with Chemoradiotherapy: How Often and How Long?
  af: Ishiki, Hiroto, et al.
  Udgivet: (2012)
• Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
  af: Doi, Toshihiko, et al.
  Udgivet: (2020)
• A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
  af: Yoshino, Takayuki, et al.
  Udgivet: (2012)
• Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
  af: Takahashi, Toshiaki, et al.
  Udgivet: (2012)
• Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
  af: Eskens, Ferry ALM, et al.
  Udgivet: (2012)